Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and effectiveness of adding
interleukin 12 (IL-12) gene therapy and L-NMMA to pembrolizumab in patients with early-stage
triple negative breast cancer (TNBC) receiving standard of care preoperative (neoadjuvant)
chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System